The Principles of Engineering Immune Cells to Treat Cancer | Zendy

Wendell A. Lim | Zendy; Carl H. June | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Principles of Engineering Immune Cells to Treat Cancer

Author(s) -

Wendell A. Lim,

Carl H. June

Publication year - 2017

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2017.01.016

Subject(s) - chimeric antigen receptor , biology , synthetic biology , immune system , computational biology , cancer cell , computer science , cancer , immunotherapy , immunology , genetics

Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research